PNPLA3 and metabolic dysfunction-associated steatotic liver disease: We previously reported that a combination of PNPLA3 and dysferlin in patients with NAFLD in Japan presented a high risk of developing HCC for both risk alleles [87], but further cases need to be studied for validation.